Gastric bypass is preferable to sleeve gastrectomy (less reflux) and can fully treat type 2 diabetes; for patients who fail dieting, bypass rather than sleeve should be chosen (2021 statement).
Original statement
ويجي يقولي أنا عايز أعمل عملية تحويل المسار بدون نقاش التكميم عملية سيئة ومشاكلها كثيرة
verbatim according to source. Translation by the project; the Arabic wording is authoritative.
Translation
Gastric bypass is preferable to sleeve gastrectomy (less reflux) and can fully treat type 2 diabetes; for patients who fail dieting, bypass rather than sleeve should be chosen (2021 statement).
Origin
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- عمليات السمنة ايه افضل عملية لصحتك وبدون خطورة (Open source)
- Published
- 31 March 2021
- Timestamp
- 0:02:26 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); wording may contain transcription errors; no timestamps available. Embedded time marker approx. [02:25] in archive transcript.
- Claimed mechanism
Bypass diverts carbohydrate load away from pancreas/liver.
- Claimed health effect
Diabetes cure; less reflux.
- Population concerned
Patients who failed diet
- Geographic restriction by Elawady
none found
Scientific assessment
Mostly true – Correct at its core, but with limitations or minor inaccuracies.
Certainty of evidence: moderate – Further research may still affect the assessment.
1. What was claimed?
Bypass better than sleeve; bypass can fully cure T2D.
2. What is demonstrably correct?
Reflux: bypass superior (SLEEVEPASS esophagitis 7% vs 31%; SM-BOSS reflux remission 60.4% vs 25.0%; STAMPEDE, A-BAR-24: GERD reported in 10% after bypass vs 27% after sleeve at 5 years). Weight loss modestly greater after bypass (SLEEVEPASS +8.4 %EWL).
3. What is wrong or exaggerated?
'Can treat diabetes completely' is overstated: diabetes remission after bypass declines (Adams 51% at 12 years; Mingrone RYGB 25% at 10 years) and SLEEVEPASS/STAMPEDE show no significant remission difference between bypass and sleeve. In STAMPEDE only 22.4% of bypass patients reached HbA1c <=6.0% without diabetes medication at 5 years (A-BAR-24; trial not powered for bypass vs sleeve). Bypass carries specific harms (A-BAR-10, A-BAR-11, A-BAR-14, I-BAR-08).
4. What remains unclear?
Individual choice depends on reflux, BMI, diabetes and patient factors.
5. Which studies support it?
A-BAR-07, I-BAR-05; Oseberg RCT 5-year remission 50% vs 20% and less pathological reflux after bypass (I-BAR-116); SM-BOSS >=10 years: conversions 5.5% vs 29.9% and less de novo GERD after bypass (I-BAR-142); lower relapse after bypass (I-BAR-131, I-BAR-134); consensus favouring bypass in significant GERD (I-BAR-113).
6. Which studies contradict it?
A-BAR-04, I-BAR-03, A-BAR-24, A-BAR-14, I-BAR-08; even after bypass, about one third of remitters relapse within 5 years (I-BAR-134) and only half were in remission at 5 years in Oseberg (I-BAR-116); bypass has more bone loss and fractures (I-BAR-123, I-BAR-126), more B12 deficiency (I-BAR-121), more postprandial hypoglycaemia (I-BAR-116), and an observational meta-analysis found higher medium-term mortality than after sleeve (sleeve HR 0.85, I-BAR-135).
7. What applies to Germany and Europe?
Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.
8. What is known about Egypt?
No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.
9. What practical conclusion is appropriate?
Procedure choice should be individual; bypass is commonly preferred when reflux exists.
Assessment details
- Rationale for certainty of evidence
Two RCTs show less reflux after bypass; diabetes 'complete cure' is overstated.
- Source quality
Short 2021 video; position differs from his later statements opposing all bariatric operations (2025: 'against any operation', 'sleeve is a crime'). Both positions are recorded; no motive is implied.
- Regional transferability
European RCTs.
- Individual exceptions
Bypass has its own risks (alcohol use disorder, bone loss, internal hernia, marginal ulcer).
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
True only under certain conditions – The claim holds only for certain doses, groups of people, preparations or circumstances.
Research question: Is gastric bypass preferable to sleeve gastrectomy (less reflux, better diabetes outcomes), and can bypass fully cure type 2 diabetes?
Research question in detail (PICO)
- Population
- Adults with severe obesity (with or without T2D/GERD) choosing a bariatric procedure
- Intervention or exposure
- Roux-en-Y gastric bypass
- Comparison
- Sleeve gastrectomy
- Geographic scope
- universal biology
- Outcomes
- GERD
- T2D remission and relapse
- Mortality
- Reoperations
- Bone, nutritional and alcohol harms
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
Norwegian trial: bypass vs sleeve in type 2 diabetes
Wågen Hauge et al.. Lancet Diabetes Endocrinol 2025 · PMID 40185112 · DOI 10.1016/S2213-8587(24)00396-6 Randomised controlled trialabstract checkednewly addedOseberg RCT: bypass doubled 5-year diabetes remission vs sleeve and caused less acid reflux.
- Actual result
- Remission 50% vs 20%; pathological reflux RD 51%.
- Methodological quality
- high (small RCT)
- Relevance
- direct
- Limitations
- n=109
Swiss trial: sleeve vs bypass after 10 years
Kraljevic et al.. JAMA Surg 2025 · PMID 39969869 · DOI 10.1001/jamasurg.2024.7052 Randomised controlled trialabstract checkednewly addedSM-BOSS: fewer conversions and less de novo GERD after bypass at >=10 years.
- Actual result
- Conversions 5.5% vs 29.9%.
- Methodological quality
- high
- Relevance
- direct
- Limitations
- Attrition
Finnish trial: sleeve vs bypass after 10 years
Salminen P et al.. JAMA Surg 2022 · PMID 35731535 · DOI 10.1001/jamasurg.2022.2229 Randomised controlled trialabstract checkedSLEEVEPASS: oesophagitis 7% vs 31%.
- Actual result
- 7% vs 31%.
- Methodological quality
- high
- Relevance
- direct
What speaks against the claim?
Meta-analysis: survival after sleeve vs bypass
Sakurai et al.. Surg Obes Relat Dis 2025 · PMID 39732586 · DOI 10.1016/j.soard.2024.11.016 Meta-analysisabstract checkednewly addedMeta-analysis: lower all-cause mortality, reoperation and hospitalisation after sleeve than bypass.
- Actual result
- Mortality HR 0.85 (0.79-0.92) SG vs RYGB.
- Methodological quality
- moderate
- Relevance
- direct
- Limitations
- Observational, short
French study: broken bones after obesity surgery
Paccou et al.. J Bone Miner Res 2020 · PMID 32187759 · DOI 10.1002/jbmr.4012 Cohort studyabstract checkednewly addedFrench cohort: fractures increased after bypass, not sleeve.
- Actual result
- Bypass HR 1.70.
- Methodological quality
- moderate
- Relevance
- direct (harm trade-off)
US study: diabetes 5 years after bypass vs sleeve
McTigue et al.. JAMA Surg 2020 · PMID 32129809 · DOI 10.1001/jamasurg.2020.0087 Cohort studyabstract checkednewly addedPCORnet: even after bypass, a third of remitters relapsed within 5 years.
- Actual result
- Relapse 33.1% (RYGB).
- Methodological quality
- moderate
- Relevance
- direct to "full cure"
- Limitations
- Observational
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
Bypass is better than sleeve for reflux and somewhat better for diabetes remission and durability, so it is commonly preferred when reflux or diabetes is prominent; but it has its own harms (more bone loss, B12 deficiency, alcohol problems, hypoglycaemia, possibly higher medium-term mortality), does not reliably cure diabetes, and procedure choice should be individual.
Why some studies weigh more
Three RCTs (SLEEVEPASS, SM-BOSS, Oseberg) for reflux/diabetes; observational data for harms and mortality.
Is a causal relationship established? Yes, established RCT comparisons for reflux and remission.
Remaining uncertainty
Long-term mortality difference between procedures.
Justified conclusion
Comparative statements mostly correct; "full cure" and a universal preference overstated.
Why do studies seem to disagree?
Bypass better for reflux/diabetes (RCTs) vs sleeve lower medium-term mortality and fewer reoperations (observational meta-analysis): these are different outcomes and represent a trade-off, not a contradiction.
Does this depend on the country?
- General biological effects
- Universal.
- Eating habits
- Not applicable (surgical procedure, not a food).
- Origin of the food
- Not applicable (surgical procedure, not a food).
- Contaminants
- Not applicable (surgical procedure, not a food).
- National production conditions
- Not applicable.
- Legal rules
- Not applicable.
- Actual monitoring data
- No Egyptian comparative data found.
A regional difference that changes the conclusion is not supported by robust data.
Statistical re-check
- Reproduce risk differences – Remission RDs 29.5% and 33.5% reproduced; hypoglycaemia RD 26% (assuming randomised denominators). recalculated
- CI symmetry of relapse HR – HR 0.75 (0.67-0.84) symmetric. recalculated
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Reflux and T2D remission, bypass vs sleeve
- Starting level
- high (randomised trials)
- Reasons for downgrading
- imprecision (small RCTs)
- Result
- moderate
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Clinical guidelines and official statements checked
- International expert consensus (Montpellier): GERD and LSG: First International Consensus Conference (I-BAR-113) (2020) · Original publication
GERD is probably the main drawback of LSG; endoscopy before (92%) and after (78%) surgery; higher-grade oesophagitis and Barrett are contraindications to LSG; RYGB recommended for uncontrolled GERD after sleeve. - ADA: Standards of Care in Diabetes-2026, Section 8 (I-DIAB-113) (2026) · Original publication
Consider metabolic surgery in type 2 diabetes with BMI >=30 (>=27.5 Asian American) (A); long-term medical and behavioural support with routine micronutrient and metabolic monitoring (B); routine psychosocial screening after surgery (C); text cites lower relapse after RYGB than sleeve (5-y relapse 33.1% vs 41.6%).
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| PubMed | 26 October 2026 | McTigue KM[au] AND sleeve gastrectomy AND gastric bypass AND diabetes AND JAMA Surg[ta] | both directions | 2 | |
| PubMed | 26 October 2026 | (Oseberg OR Hofso D[au]) AND gastric bypass AND sleeve gastrectomy AND diabetes remission AND randomised | both directions | 12 | |
| PubMed | 26 October 2026 | (sleeve gastrectomy[ti]) AND (gastroesophageal reflux[tiab] OR GERD[tiab]) AND (de novo[tiab]) AND (systematic review[pt] OR meta-analysis[pt] OR randomized controlled trial[pt]) | supporting evidence | 22 | |
| Europe PMC | 26 October 2026 | (TITLE:"bariatric" OR TITLE:"sleeve gastrectomy" OR TITLE:"metabolic surgery") AND (TITLE:"mortality" OR TITLE:"survival" OR TITLE:"life expectancy") AND (PUB_TYPE:"Meta-Analysis" OR TITLE:"meta-analysis") AND PUB_YEAR:[2019 TO 2026] | contradicting evidence | 14 |
Open questions
Long-term mortality comparison in RCTs.
How deeply was this checked?
18 linked studies: 3 checked in full text (3 of them with a structured risk-of-bias assessment), 15 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: Mostly true (moderate)
- 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: Mostly true (moderate)
Unchanged (“Mostly true”, moderate). New RCT data (Oseberg 5 y, SM-BOSS 10 y) strengthen the comparative part; new harm/mortality data strengthen the caveats.
New sources: I-BAR-113 I-BAR-116 I-BAR-131 I-BAR-134 I-BAR-142 I-BAR-121 I-BAR-123 I-BAR-126 I-BAR-135
In plain language
In a 2021 video Elawady said that sleeve gastrectomy is a bad operation because of reflux and that patients who cannot lose weight with diet should choose a gastric bypass, which can 'completely' treat diabetes. The reflux part matches randomized trials. The idea of a complete cure of diabetes is too optimistic, because diabetes returns in many patients over the years. In later videos (2025) he opposed all such operations.
Studies on this claim
Studies supporting the claim (7)
-
Finnish trial: sleeve vs bypass after 10 years
Salminen P et al.. JAMA Surg 2022 · PMID 35731535 · DOI 10.1001/jamasurg.2022.2229Randomised controlled trialcited by the Tayebat archiveabstract checked★ key studyEsophagitis was found in 31% after sleeve vs 7% after bypass; Barrett's esophagus was 4% in both groups.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare sleeve vs bypass
- How was the study done?
RCT with 10-year follow-up
- How many people, animals or samples were studied?
240 patients
- What was actually found?
More esophagitis after sleeve; Barrett's equal
- How large was the observed effect?
31% vs 7%; BE 4% vs 4%
- What do the results mean in everyday life?
Sleeve often causes reflux damage; bypass less so
- What are the study's limitations?
Attrition; small
- What does it say about Elawady's specific claim?
Supports reflux claim, not sleeve-specific Barrett's
- Do the results apply to Germany and Europe?
Directly European
- What can explicitly not be concluded from this study?
Cancer risk
-
Swiss trial: sleeve vs bypass
Peterli R et al.. JAMA 2018 · PMID 29340679 · DOI 10.1001/jama.2017.20897Randomised controlled trialindependent cross-checkabstract checked★ key studyReflux got worse in about 32% after sleeve vs 6% after bypass.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare procedures
- How was the study done?
RCT
- How many people, animals or samples were studied?
217
- What was actually found?
More reflux after sleeve
- How large was the observed effect?
31.8% vs 6.3%
- What do the results mean in everyday life?
Reflux is common but not universal
- What are the study's limitations?
Exploratory reflux outcome
- What does it say about Elawady's specific claim?
Supports increase, refutes 'inevitable'
- Do the results apply to Germany and Europe?
European
- What can explicitly not be concluded from this study?
Long-term BE
-
International experts on reflux and sleeve
Assalia et al.. Obes Surg 2020 · PMID 32533520 · DOI 10.1007/s11695-020-04749-0Guideline / position statementindependent cross-checkabstract checkedExperts agreed that reflux is probably the main drawback of sleeve and that bypass is preferable when severe reflux exists.
Bypass preferred for significant GERD/Barrett.
Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Agree on GERD management
- How was the study done?
Expert consensus
- How many people, animals or samples were studied?
46 experts
- What was actually found?
Endoscopy before/after; bypass for severe GERD
- How large was the observed effect?
Agreement %
- What do the results mean in everyday life?
Doctors take reflux after sleeve seriously
- What are the study's limitations?
Opinion-based
- What does it say about Elawady's specific claim?
Supports reflux concern
- Do the results apply to Germany and Europe?
International
- What can explicitly not be concluded from this study?
Does not condemn sleeve generally
-
Norwegian trial: bypass vs sleeve in type 2 diabetes
Wågen Hauge et al.. Lancet Diabetes Endocrinol 2025 · PMID 40185112 · DOI 10.1016/S2213-8587(24)00396-6Randomised controlled trialindependent cross-checkabstract checked★ key studyAfter 5 years, diabetes was in remission in 50% after bypass vs 20% after sleeve; acid reflux was more common after sleeve, but Barrett changes were similar.
Bypass superior for T2D remission (50% vs 20%) and pathological reflux; but only half in remission and more hypoglycaemia.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare RYGB and SG in T2D
- How was the study done?
Randomised trial
- How many people, animals or samples were studied?
109
- What was actually found?
Bypass better for remission and weight; sleeve more acid reflux
- How large was the observed effect?
RD 29.5%
- What do the results mean in everyday life?
Bypass helps diabetes more but is not a cure
- What are the study's limitations?
Small, single centre
- What does it say about Elawady's specific claim?
Supports bypass preference for diabetes/reflux; contradicts "complete cure"
- Do the results apply to Germany and Europe?
Directly European
- What can explicitly not be concluded from this study?
Long-term hard outcomes
-
Meta-analysis: diabetes returning after bypass
Yu et al.. Obes Surg 2021 · PMID 34505971 · DOI 10.1007/s11695-021-05692-4Meta-analysisindependent cross-checkabstract checkedAbout 3 in 10 people whose diabetes went into remission after bypass later relapsed; relapse was less common than after sleeve.
Lower relapse after RYGB than SG (HR 0.73).
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Relapse after RYGB
- How was the study done?
Meta-analysis
- How many people, animals or samples were studied?
17 studies
- What was actually found?
Relapse 30%
- How large was the observed effect?
HR 0.73 vs SG
- What do the results mean in everyday life?
Remission is not always permanent
- What are the study's limitations?
Observational
- What does it say about Elawady's specific claim?
Supports erosion claim
- Do the results apply to Germany and Europe?
Applicable
- What can explicitly not be concluded from this study?
Effect on complications
-
US study: diabetes 5 years after bypass vs sleeve
McTigue et al.. JAMA Surg 2020 · PMID 32129809 · DOI 10.1001/jamasurg.2020.0087Cohort studyindependent cross-checkabstract checked★ key studyDiabetes remission was slightly more common and relapse less common after bypass; still, about 1 in 3 remitted bypass patients relapsed within 5 years.
RYGB slightly better remission and less relapse than SG; but relapse common after RYGB too.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare T2D outcomes RYGB vs SG
- How was the study done?
Cohort
- How many people, animals or samples were studied?
9,710
- What was actually found?
Relapse 33% vs 42%
- How large was the observed effect?
Relapse HR 0.75
- What do the results mean in everyday life?
Bypass a bit better; neither is a guaranteed cure
- What are the study's limitations?
Observational
- What does it say about Elawady's specific claim?
Supports relapse claim; contradicts "complete cure"
- Do the results apply to Germany and Europe?
Plausible
- What can explicitly not be concluded from this study?
Hard outcomes
-
Swiss trial: sleeve vs bypass after 10 years
Kraljevic et al.. JAMA Surg 2025 · PMID 39969869 · DOI 10.1001/jamasurg.2024.7052Randomised controlled trialindependent cross-checkabstract checked★ key studyAfter more than 10 years, 3 in 10 sleeve patients needed a conversion operation (for reflux or weight) vs about 1 in 20 after bypass; new reflux was more common after sleeve.
Conversions 29.9% after SG vs 5.5% after RYGB; better GERD results after RYGB.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare long-term SG and RYGB
- How was the study done?
RCT
- How many people, animals or samples were studied?
217
- What was actually found?
More conversions and de novo GERD after SG
- How large was the observed effect?
29.9% vs 5.5% conversions
- What do the results mean in everyday life?
Sleeve has more long-term reflux problems
- What are the study's limitations?
Attrition
- What does it say about Elawady's specific claim?
Supports reflux and bypass-preference parts
- Do the results apply to Germany and Europe?
Directly European
- What can explicitly not be concluded from this study?
Mortality differences
No study in this group is marked as key.
Studies contradicting or limiting the claim (10)
-
12 years after gastric bypass
Adams TD et al.. N Engl J Med 2017 · PMID 28930514 · DOI 10.1056/NEJMoa1700459Cohort studycited by the Tayebat archivefull text, structured risk-of-bias assessment★ key studyHalf of the patients with diabetes were still in remission after 12 years; new diabetes was about 90% less frequent than in non-operated people.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Long-term outcomes
- How was the study done?
Prospective controlled cohort
- How many people, animals or samples were studied?
1156 adults
- What was actually found?
Remission declines but benefit persists
- How large was the observed effect?
Remission 51% at 12 y; incident T2D OR 0.08
- What do the results mean in everyday life?
Relapse happens, but many stay in remission
- What are the study's limitations?
Non-randomized; small diabetic subgroup; many controls later had surgery; mostly women in Utah
- What does it say about Elawady's specific claim?
Relapse claim true; 'benefit erodes away' overstated
- Do the results apply to Germany and Europe?
Applicable
- What can explicitly not be concluded from this study?
Exact causal effect; outcomes for sleeve gastrectomy
-
Italian 10-year diabetes surgery trial
Mingrone G et al.. Lancet 2021 · PMID 33485454 · DOI 10.1016/S0140-6736(20)32649-0Randomised controlled trialindependent cross-checkabstract checked★ key studyMore than half of those in remission at 2 years relapsed, but their sugar control stayed good (HbA1c 6.7%) and complications were fewer than with medicines alone.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Durability
- How was the study done?
RCT
- How many people, animals or samples were studied?
60
- What was actually found?
Relapse frequent; control better
- How large was the observed effect?
RR complications 0.07
- What do the results mean in everyday life?
Relapse does not mean the benefit is lost
- What are the study's limitations?
Tiny
- What does it say about Elawady's specific claim?
Partly supports
- Do the results apply to Germany and Europe?
European
- What can explicitly not be concluded from this study?
Generalizability
-
Alcohol and drugs after surgery
King WC et al.. Surg Obes Relat Dis 2017 · PMID 28528115 · DOI 10.1016/j.soard.2017.03.021Cohort studycited by the Tayebat archivefull text, structured risk-of-bias assessmentOne in five bypass patients reported new alcohol problem symptoms within 5 years.
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
SUD
- How was the study done?
Cohort
- How many people, animals or samples were studied?
2003
- What was actually found?
Higher after RYGB
- How large was the observed effect?
AHR 2.08
- What do the results mean in everyday life?
Alcohol risk is real, mainly after bypass
- What are the study's limitations?
No non-surgical control; self-reported screening symptoms; 22-34% missing at each follow-up; sleeve not studied
- What does it say about Elawady's specific claim?
Supports
- Do the results apply to Germany and Europe?
Applicable
- What can explicitly not be concluded from this study?
Sleeve-specific risk
-
Swedish study: fractures after gastric bypass
Axelsson KF et al.. J Bone Miner Res 2018 · PMID 30011091 · DOI 10.1002/jbmr.3553Cohort studyindependent cross-checkabstract checkedFracture risk was about 26-32% higher than in similar people without surgery.
Does the study support the specific claim? Yes · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Fracture
- How was the study done?
Matched cohort
- How many people, animals or samples were studied?
~78,000
- What was actually found?
Higher risk
- How large was the observed effect?
HR 1.26-1.32
- What do the results mean in everyday life?
Bone protection is important after bypass
- What are the study's limitations?
Short follow-up
- What does it say about Elawady's specific claim?
Supports (bypass)
- Do the results apply to Germany and Europe?
European
- What can explicitly not be concluded from this study?
Sleeve risk
-
Bowel obstruction after gastric bypass
Elms L et al.. Surg Endosc 2014 · PMID 24380988 · DOI 10.1007/s00464-013-3361-1Case series / case reportcited by the Tayebat archiveabstract checkedAbout 4 in 100 patients needed another operation for possible bowel obstruction.
Does the study support the specific claim? Unclear · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Complication causes
- How was the study done?
Retrospective review
- How many people, animals or samples were studied?
2395
- What was actually found?
3.9% reoperation
- How large was the observed effect?
3.9%
- What do the results mean in everyday life?
Late complications occur
- What are the study's limitations?
Single centre
- What does it say about Elawady's specific claim?
General harm, not sleeve-specific
- Do the results apply to Germany and Europe?
Applicable
- What can explicitly not be concluded from this study?
Comparison with non-surgery
-
Ulcers after gastric bypass
Sverdén E et al.. Ann Surg 2016 · PMID 26106845 · DOI 10.1097/SLA.0000000000001300Cohort studycited by the Tayebat archiveabstract checkedDiabetes and earlier ulcers increased the risk of ulcers at the new stomach connection.
Does the study support the specific claim? Unclear · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Risk factors
- How was the study done?
Registry cohort
- How many people, animals or samples were studied?
20,294
- What was actually found?
See results
- How large was the observed effect?
HR 1.26-2.70
- What do the results mean in everyday life?
Ulcers are a known complication
- What are the study's limitations?
Registry coding
- What does it say about Elawady's specific claim?
Indirect
- Do the results apply to Germany and Europe?
European
- What can explicitly not be concluded from this study?
Incidence vs non-surgery
-
Trials comparing bypass and sleeve: vitamin and iron deficiency
Kwon et al.. Obes Rev 2022 · PMID 35048495 · DOI 10.1111/obr.13419Meta-analysisindependent cross-checkabstract checkedAnaemia and iron deficiency were similar after bypass and sleeve, but B12 deficiency was about twice as common after bypass.
Bypass carries higher B12-deficiency risk than sleeve.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Compare deficiencies RYGB vs SG
- How was the study done?
Meta-analysis of RCTs
- How many people, animals or samples were studied?
10 RCTs
- What was actually found?
B12 deficiency higher after RYGB
- How large was the observed effect?
RR 1.86
- What do the results mean in everyday life?
Type of operation matters
- What are the study's limitations?
Few trials
- What does it say about Elawady's specific claim?
Refines the claim
- Do the results apply to Germany and Europe?
Applicable
- What can explicitly not be concluded from this study?
Very long-term rates
-
French study: broken bones after obesity surgery
Paccou et al.. J Bone Miner Res 2020 · PMID 32187759 · DOI 10.1002/jbmr.4012Cohort studyindependent cross-checkabstract checked★ key studySerious osteoporotic fractures increased after gastric bypass (about 70% more) but not after sleeve.
Bypass has higher fracture risk than sleeve.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Fracture risk by operation
- How was the study done?
National cohort
- How many people, animals or samples were studied?
81,984
- What was actually found?
Bypass HR 1.70; sleeve not increased
- How large was the observed effect?
HR 1.22 overall
- What do the results mean in everyday life?
Bone risk depends on operation
- What are the study's limitations?
Administrative data
- What does it say about Elawady's specific claim?
Limits the claim for sleeve
- Do the results apply to Germany and Europe?
Directly European
- What can explicitly not be concluded from this study?
Very long-term risk
-
Trial: bone after bypass vs sleeve
Hofsø et al.. J Clin Endocrinol Metab 2021 · PMID 33150385 · DOI 10.1210/clinem/dgaa808Randomised controlled trialindependent cross-checkabstract checkedHip and spine bone density fell more after bypass than after sleeve.
Bypass carries more bone loss than sleeve.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Bone effects RYGB vs SG
- How was the study done?
RCT
- How many people, animals or samples were studied?
92
- What was actually found?
More bone loss after bypass
- How large was the observed effect?
Spine -4.2% difference
- What do the results mean in everyday life?
Bypass is harder on bone
- What are the study's limitations?
Small, short
- What does it say about Elawady's specific claim?
Refines the claim
- Do the results apply to Germany and Europe?
Directly European
- What can explicitly not be concluded from this study?
Fracture risk
-
Meta-analysis: survival after sleeve vs bypass
Sakurai et al.. Surg Obes Relat Dis 2025 · PMID 39732586 · DOI 10.1016/j.soard.2024.11.016Meta-analysisindependent cross-checkabstract checkedSleeve was associated with about 15% lower death risk than bypass over about 3 years, but needed more revision operations.
SG associated with lower mortality, reoperation and hospitalisation than RYGB, but more revisions.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Mortality SG vs RYGB
- How was the study done?
Meta-analysis
- How many people, animals or samples were studied?
333,713
- What was actually found?
SG HR 0.85
- How large was the observed effect?
HR 0.85
- What do the results mean in everyday life?
Sleeve is not riskier for survival than bypass
- What are the study's limitations?
Observational, short
- What does it say about Elawady's specific claim?
Limits bypass-preferred claim
- Do the results apply to Germany and Europe?
Applicable
- What can explicitly not be concluded from this study?
Long-term difference
No study in this group is marked as key.
Studies with mixed or unclear results (1)
-
STAMPEDE: surgery vs medicines for diabetes
Schauer PR et al.. N Engl J Med 2017 · PMID 28199805 · DOI 10.1056/NEJMoa1600869Randomised controlled trialcited by the Tayebat archivefull text, structured risk-of-bias assessmentAfter 5 years, 23-29% of operated patients reached near-normal HbA1c vs 5% with medicines alone.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Diabetes RCT
- How was the study done?
RCT
- How many people, animals or samples were studied?
150
- What was actually found?
Surgery better
- How large was the observed effect?
29%/23% vs 5%
- What do the results mean in everyday life?
Surgery helps more, but most did not reach the target and only 15-22% reached it without diabetes medicines
- What are the study's limitations?
Small single-centre trial; not blinded; more drop-outs in the medical group; ITT result not significant
- What does it say about Elawady's specific claim?
Contradicts 'benefit erodes away'
- Do the results apply to Germany and Europe?
Applicable
- What can explicitly not be concluded from this study?
Hard outcomes
No study in this group is marked as key.
Regional context
Germany / EU
Most key data are European (Sweden SOS/SOReg, Finland SLEEVEPASS, Switzerland SM-BOSS). European and international society guidelines consider bariatric surgery for severe obesity with lifelong follow-up.
Egypt
No Egypt-specific outcome data were identified in this review. Elawady states in a transcript that sleeve gastrectomy is very widely performed in Egypt ('مصر كلها بتعملها'); the procedure-specific risks (reflux, deficiencies) apply wherever it is performed, and follow-up quality (supplements, endoscopy, mental-health screening) determines part of the risk.
What applies in my country?
General scientific assessment
Mostly true Reflux and diabetes comparisons favour bypass, but bypass does not fully cure diabetes in most patients and has its own risks, so it is not the right choice for everyone.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Effect of Laparoscopic Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial.. Salminen P et al.. JAMA Surg 2022 · PMID 35731535 · DOI 10.1001/jamasurg.2022.2229
- Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial.. Peterli R et al.. JAMA 2018 · PMID 29340679 · DOI 10.1001/jama.2017.20897
- Gastroesophageal Reflux and Laparoscopic Sleeve Gastrectomy: Results of the First International Consensus Conference.. Assalia et al.. Obes Surg 2020 · PMID 32533520 · DOI 10.1007/s11695-020-04749-0
- Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial.. Wågen Hauge et al.. Lancet Diabetes Endocrinol 2025 · PMID 40185112 · DOI 10.1016/S2213-8587(24)00396-6
- Meta-analysis of Long-Term Relapse Rate of Type 2 Diabetes Following Initial Remission After Roux-en-Y Gastric Bypass.. Yu et al.. Obes Surg 2021 · PMID 34505971 · DOI 10.1007/s11695-021-05692-4
- Comparing the 5-Year Diabetes Outcomes of Sleeve Gastrectomy and Gastric Bypass: The National Patient-Centered Clinical Research Network (PCORNet) Bariatric Study.. McTigue et al.. JAMA Surg 2020 · PMID 32129809 · DOI 10.1001/jamasurg.2020.0087
- Long-Term Outcomes of Laparoscopic Roux-en-Y Gastric Bypass vs Laparoscopic Sleeve Gastrectomy for Obesity: The SM-BOSS Randomized Clinical Trial.. Kraljevic et al.. JAMA Surg 2025 · PMID 39969869 · DOI 10.1001/jamasurg.2024.7052
- Weight and Metabolic Outcomes 12 Years after Gastric Bypass.. Adams TD et al.. N Engl J Med 2017 · PMID 28930514 · DOI 10.1056/NEJMoa1700459
- Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial.. Mingrone G et al.. Lancet 2021 · PMID 33485454 · DOI 10.1016/S0140-6736(20)32649-0
- Alcohol and other substance use after bariatric surgery: prospective evidence from a U.S. multicenter cohort study.. King WC et al.. Surg Obes Relat Dis 2017 · PMID 28528115 · DOI 10.1016/j.soard.2017.03.021
- Fracture Risk After Gastric Bypass Surgery: A Retrospective Cohort Study.. Axelsson KF et al.. J Bone Miner Res 2018 · PMID 30011091 · DOI 10.1002/jbmr.3553
- Causes of small bowel obstruction after Roux-en-Y gastric bypass: a review of 2,395 cases at a single institution.. Elms L et al.. Surg Endosc 2014 · PMID 24380988 · DOI 10.1007/s00464-013-3361-1
- Risk Factors for Marginal Ulcer After Gastric Bypass Surgery for Obesity: A Population-based Cohort Study.. Sverdén E et al.. Ann Surg 2016 · PMID 26106845 · DOI 10.1097/SLA.0000000000001300
- Comparative risk of anemia and related micronutrient deficiencies after Roux-en-Y gastric bypass and sleeve gastrectomy in patients with obesity: An updated meta-analysis of randomized controlled trials.. Kwon et al.. Obes Rev 2022 · PMID 35048495 · DOI 10.1111/obr.13419
- Gastric Bypass But Not Sleeve Gastrectomy Increases Risk of Major Osteoporotic Fracture: French Population-Based Cohort Study.. Paccou et al.. J Bone Miner Res 2020 · PMID 32187759 · DOI 10.1002/jbmr.4012
- Bone Mineral Density and Turnover After Sleeve Gastrectomy and Gastric Bypass: A Randomized Controlled Trial (Oseberg).. Hofsø et al.. J Clin Endocrinol Metab 2021 · PMID 33150385 · DOI 10.1210/clinem/dgaa808
- Comparative survival of sleeve gastrectomy versus Roux-en-Y gastric bypass in adults with obesity: a systematic review and meta-analysis.. Sakurai et al.. Surg Obes Relat Dis 2025 · PMID 39732586 · DOI 10.1016/j.soard.2024.11.016
- Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes.. Schauer PR et al.. N Engl J Med 2017 · PMID 28199805 · DOI 10.1056/NEJMoa1600869